Transaction #22939 · Form 4 · 0001493152-26-047473
Grace Therapeutics, Inc. · Purchase · Common Stock, par value $0.0001 per share
Grace Therapeutics, Inc. · Transacted October 14, 2026 · Filed October 16, 2026
What does this filing report?
An SEC Form 4 filing for Grace Therapeutics, Inc. records a purchase involving Common Stock, par value $0.0001 per share on October 14, 2026. The reported quantity was 11,233. The filing date is October 16, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Grace Therapeutics, Inc.
- Company CIK
- 0001444192
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 11,233
- Reported price
- 1.9349 · See footnotes
- Reference value
- 21,734.7317
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 2,884,522
- Ownership description
- By Opaleye, L.P.
- SEC acceptance time
- Oct 16, 2026, 8:42 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Opaleye Management Inc. ↗
10% owner
CIK 0001595855
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
- F2
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.98. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
- F3
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.95. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
- F4
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $1.90. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
- F5
- Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.